Endometrial cancer is the fourth most common cancer among women in the United States, with more than 69,000 new cases expected in 2025. Yet many diagnoses occur late, especially among women who face inconclusive imaging, discomfort with biopsy procedures, or limited access to specialty care. Research shows that nearly 30 percent of biopsies result in insufficient tissue, requiring repeat procedures and delaying diagnosis.

EdenDx, powered by INEX’s epiHERA™ technology, is a liquid-based cytology test that offers a simpler path to early detection of endometrial cancer. An endocervical sample is collected during a routine pelvic exam using a cervical brush or broom and preserved in a ThinPrep® vial. The test identifies hypermethylation of two genes, CDO1 and CELF4, which are strongly associated with endometrial cancer.  Results are delivered within 3 to 7 days, helping providers assess risk and make timely, informed clinical decisions.